NewAmsterdam Operating Income from 2010 to 2024
| NAMSW Stock | 9.06 0.63 6.50% |
Operating Income | First Reported 2010-12-31 | Previous Quarter -165.7 M | Current Value -157.4 M | Quarterly Volatility 54.7 M |
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Tax Provision of 28.4 K, Net Interest Income of 3.6 M or Interest Income of 11.8 M, as well as many indicators such as Price To Sales Ratio of 68.31, Dividend Yield of 0.0 or PTB Ratio of 3.02. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
NewAmsterdam | Operating Income |
Latest NewAmsterdam Pharma's Operating Income Growth Pattern
Below is the plot of the Operating Income of NewAmsterdam Pharma over the last few years. Operating Income is the amount of profit realized from NewAmsterdam Pharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of NewAmsterdam Pharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. NewAmsterdam Pharma's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
NewAmsterdam Operating Income Regression Statistics
| Arithmetic Mean | (27,796,541) | |
| Coefficient Of Variation | (196.92) | |
| Mean Deviation | 36,069,015 | |
| Median | (5,429,000) | |
| Standard Deviation | 54,736,874 | |
| Sample Variance | 2996.1T | |
| Range | 162.4M | |
| R-Value | (0.62) | |
| Mean Square Error | 1995.8T | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | (7,559,279) | |
| Total Sum of Squares | 41945.8T |
NewAmsterdam Operating Income History
About NewAmsterdam Pharma Financial Statements
NewAmsterdam Pharma investors use historical fundamental indicators, such as NewAmsterdam Pharma's Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NewAmsterdam Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Income | -165.7 M | -157.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.